Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.
Choose your country
Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.
You are now leaving www.kedrion.it. Medical information including licensed uses may be different outside of Italy.